{"id":"https://openalex.org/W823948869","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","title":"Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.","display_name":"Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.","alternate_titles":[],"publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W823948869","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","mag":"823948869"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.3031","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W823948869"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://lirias.kuleuven.be/bitstream/123456789/656705/2/Meeting%20Library%20_%20Phase%20I%20trial%20of%20volasertib%20%28BI%206727%29%2c%20a%20polo-like%20kinase%201%20%28Plk1%29%20inhibitor%2c%20in%20combination%20with%20cisplatin%20or%20carb.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065801156","display_name":"Am\u00e9lie Deleporte","orcid":"https://orcid.org/0000-0001-6694-0116","observed_orcids":["https://orcid.org/0000-0001-6694-0116"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Deleporte","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026692589","display_name":"Herlinde Dumez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Dumez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010064853","display_name":"Ahmad Hussein Awada","orcid":"https://orcid.org/0000-0001-7412-9163","observed_orcids":["https://orcid.org/0000-0001-7412-9163"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Awada","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071930365","display_name":"Jo Costermans","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Costermans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037366947","display_name":"Marie-Anne Meeus","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Meeus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002311944","display_name":"Thierry Berghmans","orcid":"https://orcid.org/0000-0001-7447-2519","observed_orcids":["https://orcid.org/0000-0001-7447-2519"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Berghmans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082297985","display_name":"Mahmoud Ould Kaci","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Ould Kaci","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072003755","display_name":"Nolwenn Juhel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Juhel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045772076","display_name":"Antonin BERGE","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Berge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077232595","display_name":"Tillmann Taube","orcid":"https://orcid.org/0000-0001-8990-576X","observed_orcids":["https://orcid.org/0000-0001-8990-576X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Taube","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021550191","display_name":"Patrick Sch\u00f6ffski","orcid":"https://orcid.org/0000-0001-5980-030X","observed_orcids":["https://orcid.org/0000-0001-5980-030X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Sch\u00f6ffski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"3031","last_page":"3031"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.01860000006854534,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/volasertib","display_name":"volasertib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/polo-like-kinase-1-inhibitor","display_name":"polo-like kinase 1 inhibitor","score":0.9620000123977661},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.8420000076293945},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8610000014305115},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9010000228881836},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9900000095367432},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9039999842643738},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9179999828338623},{"id":"https://openalex.org/keywords/qtc-prolongation","display_name":"QTc prolongation","score":0.9599999785423279},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8119999766349792},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.9409999847412109},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8740000128746033},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9710000157356262}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8529084920883179},{"id":"https://openalex.org/C146276462","wikidata":"https://www.wikidata.org/wiki/Q21131841","display_name":"PLK1","level":4,"score":0.6597764492034912},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6574963331222534},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6232883930206299},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5516256093978882},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5350853800773621},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.46879348158836365},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3853893578052521},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.37495675683021545},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3550545573234558},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3393694758415222},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3368385434150696},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32295727729797363},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.15840217471122742}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.3031","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3031","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:lirias2repo.kuleuven.be:123456789/656705","doi":null,"is_oa":true,"landing_page_url":"https://lirias.kuleuven.be/handle/123456789/656705","pdf_url":"https://lirias.kuleuven.be/bitstream/123456789/656705/2/Meeting%20Library%20_%20Phase%20I%20trial%20of%20volasertib%20%28BI%206727%29%2c%20a%20polo-like%20kinase%201%20%28Plk1%29%20inhibitor%2c%20in%20combination%20with%20cisplatin%20or%20carb.pdf","source":{"id":"https://openalex.org/S7407055369","display_name":"Lirias","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2011 ASCO Annual Meeting, Chicago, Illinois","raw_type":"info:eu-repo/semantics/publishedVersion"},{"id":"pmh:oai:dipot.ulb.ac.be:2013/116038","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/116038","pdf_url":null,"source":{"id":"https://openalex.org/S4306401063","display_name":"D\u00e9p\u00f4t institutionnel de l'Universit\u00e9 libre de Bruxelles (Universit\u00e9 Libre de Bruxelles)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I132053463","host_organization_name":"Universit\u00e9 Libre de Bruxelles","host_organization_lineage":["https://openalex.org/I132053463"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of clinical oncology, 29 (15","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:lirias2repo.kuleuven.be:123456789/656705","doi":null,"is_oa":true,"landing_page_url":"https://lirias.kuleuven.be/handle/123456789/656705","pdf_url":"https://lirias.kuleuven.be/bitstream/123456789/656705/2/Meeting%20Library%20_%20Phase%20I%20trial%20of%20volasertib%20%28BI%206727%29%2c%20a%20polo-like%20kinase%201%20%28Plk1%29%20inhibitor%2c%20in%20combination%20with%20cisplatin%20or%20carb.pdf","source":{"id":"https://openalex.org/S7407055369","display_name":"Lirias","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2011 ASCO Annual Meeting, Chicago, Illinois","raw_type":"info:eu-repo/semantics/publishedVersion"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W823948869.pdf","grobid_xml":"https://content.openalex.org/works/W823948869.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2598962029","https://openalex.org/W2156815349","https://openalex.org/W2501864253","https://openalex.org/W2085247930","https://openalex.org/W2603128670","https://openalex.org/W2023678160","https://openalex.org/W2184535556","https://openalex.org/W1427460457","https://openalex.org/W2462851358","https://openalex.org/W2979393870"],"abstract_inverted_index":{"3031":[0],"Background:":[1],"Volasertib":[2],"(V)":[3],"is":[4,91,358],"a":[5,13,45,103,166,186],"potent":[6],"and":[7,24,68,176,183,190,196,222,309,315,329,336,339,341,361,373],"highly":[8],"selective":[9],"inhibitor":[10],"of":[11,16,38,49,102,106,118,169,188,247,331,365,389,395],"Plk1,":[12],"key":[14],"regulator":[15],"cell-cycle":[17],"progression.":[18],"Preclinical":[19],"data":[20],"showed":[21],"that":[22],"V":[23,50,78,184,351,397],"Cisplatin":[25],"(Cis)":[26],"or":[27,57,84,240,356],"carboplatin":[28],"(Ca)":[29],"combination":[30,52,163,353],"may":[31],"confer":[32],"additional":[33],"benefit.":[34],"Methods:":[35],"Sequential":[36],"cohorts":[37,369],"3":[39,65,217,239,342],"to":[40,74,377],"6":[41,75,107,348],"patients":[42],"(pts)":[43],"received":[44,161],"single":[46],"2-hour":[47],"infusion":[48],"in":[51,173,180,193,207,224,270,277,294,303,318,327,333,352],"with":[53,296,312,354],"Cis":[54,67,355,387],"(arm":[55,59,132],"A)":[56],"Ca":[58,69,357,393],"B),":[60],"on":[61],"day":[62],"1":[63,206,223,310],"every":[64],"weeks.":[66],"were":[70,127,131,204,245,291],"given":[71],"for":[72,165,185,219],"up":[73],"cycles":[76],"(Cy),":[77],"was":[79,268,325],"continued":[80],"until":[81],"disease":[82,324],"progression":[83],"unacceptable":[85],"toxicity.":[86],"Maximum":[87],"tolerated":[88,360],"dose":[89,96],"(MTD)":[90],"defined":[92],"as":[93],"the":[94,162,379],"highest":[95],"at":[97,210,227,285,370],"which":[98],"\u22651":[99],"pt":[100,244,311],"out":[101],"maximum":[104],"(max)":[105],"experienced":[108],"Dose":[109,382],"Limiting":[110],"Toxicity":[111],"(DLT)":[112],"during":[113],"Cy":[114,171,178,192],"1.":[115],"Results:":[116],"As":[117],"January":[119],"14,":[120],"2011,":[121],"36":[122],"pts":[123,248,272,295,332,343,390,396],"(18":[124],"each":[125],"arm)":[126],"treated.":[128],"Pt":[129],"characteristics":[130],"A/B):":[133,250],"median":[134,167],"age":[135],"52/57.5":[136],"years,":[137],"male":[138],"39/72%,":[139],"ECOG":[140],"PS":[141,144],"0:":[142],"44/39%,":[143],"1:":[145],"50/61%.":[146],"Tumors":[147],"were:":[148],"NSCLC":[149],"(22%),":[150],"sarcoma":[151,302],"(14%),":[152],"colorectal":[153],"cancer":[154],"(11%),":[155,157],"melanoma":[156],"other":[158],"(42%).":[159],"Pts":[160],"therapy":[164],"[range]":[168],"4":[170,214,231,241],"[1-6]":[172],"arm":[174,181,208,225,249,304,319,334],"A":[175,195,209,305,335],"2":[177,200,271,293],"[2-6]":[179],"B":[182,197,226,320,337],"max":[187],"15":[189],"11":[191],"arms":[194,279],"respectively.":[198],"Only":[199],"DLTs":[201],"(Cy":[202],"1)":[203],"observed,":[205],"DL":[211,228],"A5":[212,372],"(grade":[213,230],"CTC":[215],"version":[216],"neutropenia":[218,253,258],">7":[220],"days)":[221],"B4":[229],"thrombocytopenia).":[232],"The":[233],"most":[234],"frequent":[235],"drug":[236],"related":[237],"grade":[238],"AEs":[242],"by":[243],"(%":[246],"anemia":[251],"6/6,":[252],"33/33,":[254],"thrombocytopenia":[255],"6/22,":[256],"febrile":[257],"6/0,":[259,261],"vomiting":[260],"fatigue":[262],"11/6.":[263],"Grade":[264],"1/2":[265],"QTc":[266],"prolongation":[267],"observed":[269],"(DL":[273,306,321],"A2,":[274,307],"B4).":[275,322],"MTD":[276],"both":[278],"has":[280],"not":[281],"yet":[282],"been":[283],"reached":[284],"predefined":[286],"DLs.":[287],"Three":[288],"partial":[289],"responses":[290],"seen:":[292],"CHOP-resistant":[297],"follicular":[298],"dendritic":[299],"reticulum":[300],"cell":[301],"A4)":[308],"heavily-pretreated":[313],"head":[314],"neck":[316],"carcinoma":[317],"Stable":[323],"reported":[326],"50%":[328],"39%":[330],"respectively,":[338],"5":[340],"had":[344],"long":[345],"stabilization":[346],"(>":[347],"Cy).":[349],"Conclusions:":[350],"well":[359],"demonstrates":[362],"preliminary":[363],"evidence":[364],"antitumor":[366],"activity.":[367],"Extension":[368],"DLs":[371],"B5":[374],"are":[375],"ongoing":[376],"confirm":[378],"recommended":[380],"doses.":[381],"levels":[383],"(DL)":[384],"Arm":[385,391],"A:":[386],"(mg/m2)/n":[388],"B:":[392],"(AUC)/n":[394],"(mg)":[398],"A1/B1":[399],"60/3":[400],"4/3":[401],"100":[402,406],"A2/B2":[403],"75/3":[404,408,412],"5/3":[405,409],"A3/B3":[407],"200":[410],"A4/B4":[411],"5/6":[413],"300":[414,418],"A5/B5":[415],"100/6":[416],"6/3":[417]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W823948869","counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
